Kamada Ltd. Book Value 2011-2026 | KMDA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Kamada Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	319 M	179 M	135 M	112 M	89.5 M	66.7 M	72.5 M	80.4 M	90 M	28.4 M	22.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
319 M	22.7 M	109 M

Quarterly Book Value Kamada Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	319 M	217 M	-	-	211 M	206 M	-	-	174 M	-	-	-	138 M	-	-	-	122 M	-	-	-	99.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
319 M	99.7 M	186 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	134 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	967 M	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	8.61 B	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	-163 M	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
ANI Pharmaceuticals ANIP	429 M	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	178 M	$ 1.41	2.17 %	$ 375 M	Britain
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	6.33 M	$ 1.51	48.04 %	$ 17 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
BioMarin Pharmaceutical BMRN	6.09 B	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	225 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	225 M	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	19.2 B	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	90.6 B	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	581 M	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	18.5 B	$ 59.6	-2.45 %	$ 121 B	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	1.66 B	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	-476 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	1.83 M	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	275 M	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Cellectis S.A. CLLS	75.9 M	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	18.3 B	$ 177.34	-3.5 %	$ 26 B	USA
Axcella Health AXLA	4.16 M	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	2.33 B	$ 412.81	-2.54 %	$ 31.3 B	USA